Share price recommendations
According to NASDAQ, Regeneron Pharmaceuticals (REGN) could report its 2Q16 financial and operating results July 14, 2016. An algorithm based on REGN’s historical reporting dates has been used to calculate the estimated release date. In this series, we’ll see what you can expect from REGN ahead of its 2Q16 earnings.
The table above shows 21 brokerage firms and their estimated target prices for REGN. The consensus 12-month target price for the company is $466.90. This translates to a ~29.8% return compared to its closing price of $359.60 on July 5, 2016.
A July 5, 2016, Bloomberg survey of 27 brokerage firms showed 51.9% “buy” ratings for Regeneron stock, 44.4% “hold” recommendations, and 3.7% “sell” recommendations.
Analyst recommendations for Regeneron’s peers
According to a Bloomberg survey of 26 analysts on July 5, 2016, 50% of them issued a “buy” rating for Amgen (AMGN), and 50% rated the stock a “hold.” The 52-week target price for AMGN is $183.74, which presents a 19.1% return potential over a 12-month period.
According to the ratings of 25 analysts in a Bloomberg consensus dated July 5, 2016, 64% rated Biogen (BIIB) a “buy,” and 36% recommended a “hold.” The 12-month target price for the stock is $330.16, a 36.4% return potential over the period.
A Bloomberg consensus of 26 analysts on July 5, 2016, indicated that 76.9% issued a “buy” rating for Celgene (CELG), and 19.2% recommended a “hold.” About 3.8% of the analysts gave the stock a “sell” rating. The 12-month target price for CELG is $137.10 with a 36.8% return potential over the one-year period.
Any direct investment in stocks is risky. To mitigate this risk, you can choose to invest in funds such as the iShares Nasdaq Biotechnology (IBB). IBB has 6.1% of its total holdings in Regeneron.
In the next part of this series, we’ll look at expectations for Regeneron in its upcoming 2Q16 earnings release.